The Oregon Clinical & Translational Research Institute and OHSU Technology Transfer & Business Development are pleased to announce the funding of two Biomedical Innovation Program drug discovery awards. A new track supports drug discovery platforms and early stage therapeutic technology projects, including validation of drug targets and the development of small molecules, antibodies, vaccines, or biologics. The BIP provides funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU, and accelerate their translation from academia to the marketplace.
Congratulations to the 2016 BIP Drug Discovery awardees:
Penny Hogarth, M.D. –Associate Professor, Molecular & Medical Genetics: “Fast-track CoACT”
Xiangshu Xiao, Ph.D. – Associate Professor, Physiology & Pharmacology, Knight Cancer Institute:
“Novel lamin-binding ligands for the treatment of triple negative breast cancer“
“I am thrilled to see the BIP expand and meet the need of support for early-stage drug discovery research at OHSU,” says OCTRI Director David Ellison, M.D. “By prioritizing commercialization outcomes, the BIP helps position technologies such that they have the best possible chance of making it to market and improving human health.”
Detailed information on both awards, including project abstracts, can be found on the OCTRI website. For more information on other OCTRI’s other research support services, please visit: www.octri.org.
OCTRI is supported by (UL1TR000128) from the National Center for Advancing Translational Science (NCATS) at the National Institutes of Health (NIH).